﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Society of Diabetic Nephropathy Prevention</PublisherName>
      <JournalTitle>Journal of Nephropathology</JournalTitle>
      <Issn>2251-8363</Issn>
      <Volume>7</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2018</Year>
        <Month>10</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>The effect of oral N-acetylcysteine on serum high sensitive CRP and plasma hemoglobin levels in end-stage renal disease patients under routine hemodialysis; a randomized placebocontrolled clinical trial</ArticleTitle>
    <FirstPage>268</FirstPage>
    <LastPage>272</LastPage>
    <ELocationID EIdType="doi">10.15171/jnp.2018.53</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Bahman</FirstName>
        <LastName>Bashardoust</LastName>
      </Author>
      <Author>
        <FirstName>Roya</FirstName>
        <LastName>Alaei</LastName>
      </Author>
      <Author>
        <FirstName>Sousan</FirstName>
        <LastName>Mohammadi Kebar</LastName>
      </Author>
      <Author>
        <FirstName>Sabah</FirstName>
        <LastName>Hasani</LastName>
      </Author>
      <Author>
        <FirstName>Afshin</FirstName>
        <LastName>Habibzadeh</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.15171/jnp.2018.53</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2017</Year>
        <Month>06</Month>
        <Day>03</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2017</Year>
        <Month>08</Month>
        <Day>18</Day>
      </PubDate>
    </History>
    <Abstract>Background: Oxidative stress and systemic inflammation is increased in end-stage renal disease (ESRD) patients. Due to the various effects of oxidative stress in ESRD patients, different antioxidants have been evaluated. Objectives: In this study, we evaluated the effect of oral N-acetylcysteine (NAC) as an antioxidant on the serum high-sensitive C-reactive protein (hs-CRP) and plasma hemoglobin levels in the ESRD patients who were under routine hemodialysis. Patients and Methods: In this randomized placebo-controlled clinical trial, 51 ESRD patients under routine hemodialysis were randomly assigned to receive NAC 1200 mg daily for 1 month (n=26) or placebo (n=25). Laboratory findings including hemoglobin, ferritin, hsCRP were measured in patients before and after treatment. Results: NAC group compared to placebo group had significantly higher ferritin levels before treatment (p=0.02) and lower phosphorus levels after treatment (p=0.03). Comparing the results before and after treatment in each group, a significant reduction in hematocrit (p=0.002), ferritin (p=0.006), hs-CRP (p=0.02) and an increase in alkaline phosphatase levels (p=0.005) in NAC group and significant reduction in calcium levels (p&lt;0.001) in placebo group was detected. No major side effects were seen. Conclusions: One month treatment with oral NAC resulted in reduced levels of hematocrit, ferritin and Hs-CRP, indicative of role of NAC in controlling inflammation in ESRD patients under hemodialysis. However, NAC was not effective in treatment of anemia, although the treatment duration was low.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">End-stage renal disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">high sensitivity CRP</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">N-acetylcysteine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hemoglobin</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>